[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-operative-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-operative-pain":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,91,0,25,[9,44,70,95,123,145,173,196,222,247,273,298,323,356,377,400,423,447,475,501,527,550,570,589,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100578354","a-comparison-between-the-efficacy-of-modified-thoracoabdominal-plane-block-via-perichondral-approach-m-tapa-and-external-oblique-intercostal-plane-block-eoipb-in-patients-undergoing-laparoscopic-cholecystectomy-surgeries-lc-100578354",false,"NCT06810206","A Comparison Between The Efficacy of Modified Thoracoabdominal Plane Block Via Perichondral Approach (M-TAPA) And External Oblique Intercostal Plane Block (EOIPB) in Patients Undergoing Laparoscopic Cholecystectomy Surgeries (LC)","A Comparison Between The Efficacy of Modified Thoracoabdominal Plane Block Via Perichondral Approach (M-TAPA) And External Oblique Intercostal Plane Block (EOIPB) in Patients Undergoing Laparoscopic Cholecystectomy Surgeries (LC): A Double-Blinded Randomized Comparative Study.","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Scheduled for Laparoscopic cholecystectomy surgery\n* ASA (American Society of Anaesthesiologists) physical status I-II\n\nExclusion Criteria:\n\n* Known allergy to local anaesthetics\n* Coagulopathy or anticoagulant use\n* Infection at the site of block\n* Chronic pain conditions\n* Advanced liver or kidney failure\n* History of abdominal surgery or trauma\n* Alcohol or drug use\n* Refusal to participate\n* Chronic opioid consumption\n* Use of painkillers in the preoperative 24hours\n* Conversion to open surgery\n* Body mass index ( BMI ) \\> 35","ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Because laparoscopic procedures have a number of benefits over open procedures, they have completely changed the surgical industry.(1) Laparoscopic cholecystectomy (LC) is a minimally invasive technique that usually yields less discomfort following surgery, shorter hospital stays, and quicker patient recovery, plus it's an economical operation. Nevertheless, it results in moderate to severe pain.(2).By using regional anesthesia techniques to effectively control pain and lessen the requirement for opioid analgesics, ERAS implementation has demonstrated significant decreases in opioid usage and improved overall patient outcomes (3). (4) To minimize the need for opioids, opioid sparing anesthesia employs a multimodal strategy that includes nonsteroidal anti-inflammatory medications, paracetamol, local anesthetics (LA), and, if feasible, regional anesthetic techniques and regional analgesia. (5) With fewer systemic side effects, regional anesthetic techniques-like nerve blocks-offer tailored pain treatment. The best regional pain management strategy for LC surgery is still unknown, though.(4) Modified Thoracoabdominal Nerves Block Through Perichondral Approach (M-TAPA) Block is a new technique defined as a modification of TAPA Block in which local anaesthetics are administered only to the underside of the perichondral surface, creating a sensory block between T5-T12 dermatomes. While the external oblique intercostal plane (EOIPB) block provides blockade of the lateral and anterior cutaneous branches of the intercostal nerves from T6\u002F7 to T10\u002F11.This study aims to compare the efficacy of both MTAPA and EOIPB in patients undergoing LC surgery .",[28],"Post Operative Pain",[30],"postoperative pain","NOT_YET_RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":22},"2026-11",{"date":39,"type":22},"2027-11",{"name":41,"class":42},"Kasr El Aini Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100634542","serratus-vs-esp-block-for-postoperative-pain-in-unilateral-breast-surgery-100634542","NCT07541040","Serratus vs ESP Block for Postoperative Pain in Unilateral Breast Surgery","Comparison of Serratus Posterior Superior Intercostal Plane Block and Erector Spinae Plane Block for Postoperative Analgesia in Unilateral Breast Surgery: A Prospective, Randomized, Assessor-Blinded Trial","Inclusion Criteria:\n\n* Female patients aged 18-65 years\n* ASA physical status I-III\n* Body mass index (BMI) between 18 and 35 kg\u002Fm²\n* Scheduled for elective unilateral breast surgery (mastectomy with or without sentinel lymph node biopsy)\n* Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n* Infection at the site of block application\n* Known allergy to local anesthetics\n* Coagulopathy or anticoagulant therapy\n* Chronic opioid use\n* Pregnancy\n* Inability to communicate or cooperate\n* Refusal to participate\n* Failed block\n* Requirement of additional intraoperative analgesia outside the study protocol\n* Development of serious intraoperative complications","FEMALE",{"count":53,"type":22},54,[25],"This prospective, randomized, assessor-blinded trial compares serratus posterior superior intercostal plane block (SPSIPB) and erector spinae plane block (ESPB) for postoperative analgesia in unilateral breast surgery. 54 patients will be randomized to receive either SPSIPB or ESPB before general anesthesia.\n\nThe primary outcome is postoperative pain scores within the first 24 hours. The secondary outcome is opioid consumption.",[28,57],"Opioid Use",[28,57],"RECRUITING","2026-08-04",{"date":62,"type":35},"2026-08-06",{"date":64,"type":35},"2026-05-01",{"date":66,"type":22},"2026-09-01",{"name":68,"class":69},"Engin Çetin","OTHER_GOV",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100582949","evaluation-of-postoperative-pain-control-in-ear-surgery-100582949","NCT06869967","Evaluation of Postoperative Pain Control in Ear Surgery","Evaluation of Ultrasound-Guided Auricularis Magnus Nerve Block for Postoperative Pain Control in Ear Surgery","Inclusion Criteria:\n\n* Patients undergoing CWD and Mastodectom\n* Patients undergoing elective surgery\n* ASA (American Society of Anesthesiologists) physical status classification I-II\n* Patients over 18 years of age\n\nExclusion Criteria:\n\n* Anticoagulant use\n* Allergy to the drugs to be used\n* ASA (American Society of Anesthesiologists) physical status classification IV-V\n* Presence of infection in the area where the block will be applied\n* Patient's refusal to accept the block application or inability to cooperate with the patient",{"count":78,"type":22},56,[25],"Middle ear surgery is the most popular procedure in ear, nose and throat surgery. Increased sympathetic stimulation after surgery can activate the sympathetic system, causing hypertension and increased heart rate. As a result of these clinical conditions, hemorrhage can occur, which can impair the quality of the surgical field, which is undesirable in middle ear surgery.Clinical studies should be conducted with auricularis magnus nerve block applied in the perioperative period in middle ear surgery and postoperative pain scores.",[28,82],"Analgesia",[84,85,86],"Regional Anesthesia","Ear Surgery","Auricularis Magnus Nerve Block",{"date":88,"type":35},"2026-08-05",{"date":90,"type":35},"2025-10-20",{"date":92,"type":22},"2027-02-15",{"name":94,"class":42},"Kocaeli University",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},"100391014","phase-4-dextenza-in-the-post-op-management-of-vitreoretinal-surgeries-100391014","NCT04371445","Dextenza in the Post-op Management of Vitreoretinal Surgeries","Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery","Inclusion Criteria:\n\n* Men and women \\>18 years old\n* Planning to undergo vitreoretinal surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.\n\nExclusion Criteria:\n\n* Patients undergoing combined cataract or glaucoma procedure, intraocular lens exchange, scleral buckle, and\u002For implant of a drug delivery system\n* History of complications, trauma, adverse events, disease in nasolacrimal region, including dacryocystitis, canaliculitis in either eye\n* Structural lid abnormalities such as ectropion or entropion in surgical eye\n* Ongoing use of systemic narcotic pain relievers\n* Presence of any intraocular inflammation (cells and flare) in the study eye at screening\u002Fbaseline\n* Pain score greater than \"0\" on the ocular pain assessment in the study eye at screening\u002Fbaseline\n* Active or chronic or recurrent uncontrolled ocular or systemic inflammatory disease, including diabetes\n* Other ocular surgeries or procedures during the study period and\u002For 6 months prior\n* Intraoperative complications\n* Patients with history of glaucoma (defined as glaucoma requiring 2 or more drops, IOP at baseline greater than 25, or advanced optic nerve cupping). Patients with glaucoma or ocular hypertension controlled with a single drop can be enrolled.\n* Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication.\n* Have used ocular, topical, or systemic NSAIDs within 7 days prior to procedure and during surgery.\n* Use of intracameral or subconjunctival NSAIDs or steroids intraoperatively.\n* Have used topical, ocular, inhaled or systemic steroids within 14 days prior to procedure\n* Are pregnant or nursing\u002Flactating\n* Participation as a subject in any clinical study within the 30 days prior to randomization.\n* Surgeries using 20 gauge or 23 gauge instruments.",{"count":103,"type":22},30,[105],"PHASE4","This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group.\n\nPatients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.",[108,109,110,111],"Vitreoretinal Surgery","Ocular Inflammation","Post-operative Pain","Post-Operative Inflammation",[113,109,111,110],"dexamethasone insert","2026-07-27",{"date":116,"type":35},"2026-07-29",{"date":118,"type":35},"2020-06-01",{"date":120,"type":22},"2027-12-01",{"name":122,"class":42},"The Cleveland Clinic",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100649831","assessment-of-post-operative-pain-after-using-cryotherapy-and-dexamethasone-100649831","NCT07738302","Assessment of Post-Operative Pain After Using Cryotherapy and Dexamethasone","Assessment of Post-Operative Pain After Using Cryotherapy and Dexamethasone in Symptomatic Irreversible Pulpitis With Acute Apical Periodontitis: A Randomized Clinical Trial.","Inclusion Criteria:\n\n* Medically free Patients. (ASA I and II)\n* Age between 20-50 years old.\n* Males \\& Females.\n* Patients' acceptance for participating in the trial through an informed consent (Appendix I)\n* Diagnosed clinically and radiographically with symptomatic irreversible pulpitis with apical peridontitits\n* No periapical radiolucency\n* Patent canals with n\n\nExclusion Criteria:\n\nNon restorable teeth.\n\n* No bleeding upon conducting access preparation.\n* Teeth presenting with:\n* History of trauma or previous endodontic treatment","20 Years","50 Years",{"count":21,"type":22},[25],"Evaluation and comparing the effect of cryotherapy and dexamethasone on inflammatory mediators and post-operative pain in symptomatic irreversible pulpitis with acute apical periodontitis.",[28],"2026-07-26",{"date":138,"type":35},"2026-07-31",{"date":140,"type":22},"2026-08",{"date":142,"type":22},"2026-09",{"name":144,"class":42},"Suez Canal University",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":152,"maxAge":19,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":43},"100636866","phase-4-impact-of-preemptive-analgesia-on-postoperative-pain-in-orthognathic-surgery-100636866","NCT07571252","Impact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery","Impact of Preemptive Analgesia on Postoperative Pain in Patients Undergoing Orthognathic Surgery: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults aged 21 to 65 years.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Scheduled to undergo orthognathic surgery including bilateral sagittal split osteotomy and Le Fort I osteotomy under general anesthesia.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Known allergy or intolerance to acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n* Renal dysfunction, defined as estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m².\n* Hepatic dysfunction, defined as liver enzyme levels greater than twice the upper limit of normal.\n* History of bleeding disorders or coagulopathy.\n* Active or recent peptic ulcer disease.\n* Current use of recreational drugs, including cannabis, that in the judgment of the investigators could interfere with anesthesia management, postoperative pain assessment, or study outcomes.\n* Any medical condition that, in the judgment of the investigators, would make participation unsafe or interfere with study participation.","21 Years",{"count":154,"type":22},72,[105],"This randomized controlled clinical trial evaluates the effect of preemptive analgesia on postoperative pain outcomes in adult patients undergoing orthognathic surgery. Participants scheduled for bilateral sagittal split osteotomy and Le Fort I osteotomy under general anesthesia will be randomized to one of three groups: intravenous acetaminophen, intravenous ibuprofen, or a control group receiving standard postoperative analgesia without preoperative medication.\n\nThe study aims to determine whether the administration of pre-surgical analgesics reduces postoperative pain intensity and analgesic requirements during the early postoperative period. Pain will be assessed using a standardized pain scale at multiple time points following surgery, and secondary outcomes will include postoperative analgesic consumption and patient satisfaction with pain control.\n\nThis investigation seeks to contribute evidence supporting multimodal analgesic strategies and improved postoperative pain management in patients undergoing orthognathic surgery.",[28,158],"Orthognathic Surgery",[160,158,161,162,163,164],"Preemptive Analgesia","Postoperative Pain","Maxillofacial Surgery","Multimodal Analgesia","Randomized controlled trial","2026-07-22",{"date":167,"type":35},"2026-07-24",{"date":142,"type":22},{"date":170,"type":22},"2027-02",{"name":172,"class":42},"University of Puerto Rico",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":180,"maxAge":18,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":43},"100548387","ql-vs-lai-for-palatoplasty-100548387","NCT06420336","QL vs LAI for Palatoplasty","Quadratus Lumborum Block for Pain Control in Unilateral Anterior Iliac Bone Graft Harvesting for Pediatric Patients Undergoing Palatoplasty: a Prospective Randomized Control Trial","Inclusion Criteria\n\n* Patients undergoing palatoplasty with autologous bone graft from the anterior iliac crest.\n* Ages 6-18 years of age\n* Planned admission post-op\n* ASA Status Range: 1-3\n\nExclusion Criteria\n\n* Contraindication to QL blocks or LAI which may include:\n* overlying infection skin at the block needle insertion site\n* coagulopathies\n* known bleeding disorders\n* Allergy to local anesthetic\n* Cognitive or developmental impairment that would limit ability to report pain.\n* Non-English Speaking\u002FWriting\n* Subjects or their parent\u002Fguardian unable or choose to not give informed consent\u002Fassent.","6 Years",{"count":182,"type":22},46,[25],"This study will consist of patients ages 6-18 who are undergoing a surgery on the hard or soft palate of the mouth (palatoplasty), with removal of bone from the front of the hip (anterior iliac bone graft harvesting). The patients will be randomized to receive either a unilateral QL block by an anesthesiologist, or local anesthetic infiltration at the surgical incision by the surgeon. The primary aim will be assessing post-operative pain in the first 48 hours after surgery. Secondary outcomes will include pain medication use in the first 48 hours after surgery, block resolution time, and evaluating any complications associated with the QL block or local anesthetic infiltration.",[110,57,186],"Cleft Palate","2026-07-07",{"date":189,"type":35},"2026-07-09",{"date":191,"type":35},"2024-06-25",{"date":193,"type":22},"2027-01-31",{"name":195,"class":42},"Medical University of South Carolina",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":43},"100645356","performance-and-safety-of-the-antalgeek-thess-monitoring-medical-device-in-the-outpatient-management-of-acute-pain-and-postoperative-recovery-100645356","NCT07680998","Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery","Evaluation of the Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery - A Single-Center, Randomized, Controlled Proof-of-Concept Study.","TRACE","Inclusion Criteria:\n\n* Patients eligible for outpatient surgery.\n* Patients undergoing surgery likely to result in moderate to severe pain.\n* Patients available for a 3-month follow-up.\n* Patients who have provided their free and informed consent.\n* Patients who have signed the consent form.\n* Patients enrolled in or covered by a health insurance plan.\n\nExclusion Criteria:\n\n* Patients participating in an interventional RIPH study involving a drug or classified as Category 1.\n* Patients in an exclusion period determined by another study.\n* Patients under judicial protection, guardianship, or conservatorship.\n* Patients unable to express consent.\n* Patient for whom it is impossible to provide informed information.\n* Pregnant, laboring, or breastfeeding patients.",{"count":205,"type":22},150,[25],"Acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year. Effective analgesic therapy in the first postoperative week is a key factor in reducing early postoperative morbidity and mortality. Poorly controlled APOP is a major risk factor for chronic postoperative pain. In France today, more and more patients undergo surgical procedures as outpatients. The challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either after outpatient surgery or after a prompt return home as part of an Enhanced Recovery After Surgery (ERAS) protocol. In outpatient surgery, postoperative pain management requires new strategies and\u002For organizational approaches to ensure high-quality pain management from the very start. The principle of analgesia for acute postoperative pain recommends: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy if maintenance therapy is insufficient, based on pain titration, using mild or strong oral opioids. Postoperative pain is the primary focus of postoperative care but the goal is also to improve postoperative recovery and enhance the patient's overall care. To date, there are no medical telemonitoring devices to support the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, enabling systematic postoperative screening for early and late warning signs of the risk of chronic pain. The Thess Monitoring device, which implements the ANTALGEEK® protocol, (TMA) was developed to optimize the efficiency of outpatient management of acute postoperative pain. It improves patients' adherence to maintenance treatment with adaptive, personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing). The aim is to ensure optimal pain resolution and improve early and late postoperative recovery during the first postoperative week. The TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain. By measuring pain scores daily during the first postoperative week, it identifies patients with a suboptimal pain trajectory who are at high risk of developing persistent pain beyond the third month. It also assesses warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3). Improving the patient care pathway via the TMA system should make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.",[28,209],"Chronic Pain",[28,211,212],"Pain Management","Monitoring","2026-07-06",{"date":215,"type":35},"2026-07-08",{"date":217,"type":35},"2025-12-01",{"date":219,"type":22},"2026-12-31",{"name":221,"class":42},"Centre Hospitalier Universitaire de Nīmes",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":43},"100542969","early-phase-1-zynrelef-vs-exparel-the-battle-of-postoperative-pain-control-after-robotic-sleeve-gastrectomy-100542969","NCT06349772","Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy","Inclusion Criteria:\n\n1. Age range: 18-65 years old\n2. Scheduled or being scheduled to undergo robotic sleeve gastrectomy by Dr. Goyal.\n3. Is able to provide written informed consent.\n4. Is able to adhere to the study visit schedule and complete all study assessments.\n\nExclusion Criteria:\n\n1. Positive urine drug screen prior to surgery\n2. History of substance abuse in the past year-by self report\n3. Patient with ongoing daily narcotic use at the time of surgery-by self report\n4. Inability to understand informed consent or read English\u002FSpanish\n5. Pregnant or lactating patients\n6. Prisoners\n7. Patients with renal or hepatic failure\n8. Bupivacaine use within 96 hours of operation\n9. Patient intolerant of opiates, nonsteroidal anti-inflammatory drug s, acetaminophen, or Zynrelef and Exparel. Subjects in all cohorts must not have any contraindications to any of the protocol-specified drugs\n10. Patient with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients",true,{"count":230,"type":22},130,[232],"EARLY_PHASE1","The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only.",[28],[236,237,238,239],"robotic surgery","sleeve gastrectomy","zynrelef","exparel",{"date":215,"type":35},{"date":242,"type":35},"2024-11-01",{"date":244,"type":22},"2028-12-01",{"name":246,"class":42},"Texas Tech University Health Sciences Center",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":255,"maxAge":4,"enrollmentInfo":256,"targetDuration":258,"studyType":259,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":272},"100447788","a-multicenter-patient-registry-on-outcomes-from-cryoanalgesia-of-the-intercostal-nerves-100447788","NCT05110989","A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves","The CryoICE™ Cryoanalgesia Registry for Pain Management in Post-cardiothoracic Surgery Via Cryoablation of the Intercostal Nerves","REDUCE","Inclusion Criteria:\n\n1. Patients whose age is 12 years or above, and are able to give informed consent\u002Fassent specific to state and national law.\n2. Patients have been scheduled by physician(s) to undergo or have undergone cryoablation of the intercostal nerves utilizing at least one AtriCure device or are similar patients treated without the use of cryoablation\n\nExclusion Criteria:\n\n1. Patient is enrolled in a concurrent trial that may impact the treatment offered by the registry devices.\n2. Patient with exclusion criteria required by local governance.\n3. Women of childbearing potential who are, or plan to become, pregnant during the time of the study","12 Years",{"count":257,"type":22},5000,"5 Years","OBSERVATIONAL","This is a retrospective and prospective, multicenter, observational patient registry to record outcomes from patients undergoing cryoablation of the intercostal nerves (cryoanalgesia) for post-operative pain management.",[28],"2026-06-26",{"date":264,"type":35},"2026-06-29",{"date":266,"type":35},"2018-06-29",{"date":268,"type":22},"2040-01",{"name":270,"class":271},"AtriCure, Inc.","INDUSTRY",11,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100525590","phase-2-perioperative-vitamin-c-to-reduce-persistent-pain-after-total-knee-arthroplasty-100525590","NCT06123715","Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty","PeRiOperative VItamin C to Reduce perSistent paIn After tOtal kNee Arthroplasty (PROVISION): a Pilot Multicentre Randomized Controlled Trial","PROVISION","Inclusion Criteria:\n\n* Patients \\>18 years old\n* Undergoing a unilateral or bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee\n\nExclusion Criteria:\n\n* TKA for infection (septic joint), fracture, ankylosing spondylitis, lupus, or psoriatic arthritis\n* History of kidney stones, acute or chronic renal failure, hemochromatosis, or glucose-6-phosphate deficiency\n* Unlikely to comply with follow-up (e.g., no fixed address, plans to move out of town)\n* Language difficulties that would impede valid completion of questionnaires\n* Planned staged bilateral TKA\n* Treating surgeon deems patient inappropriate for inclusion in trial\n* Any allergy or sensitivity to milk\n* Pregnant or planning to become pregnant during the study",{"count":282,"type":22},400,[284],"PHASE2","Phase II Multicentre, pilot, parallel-group, blinded, 1:1 randomized controlled trial to determine the feasibility of conducting a larger definitive trail of using vitamin C to reduce persistent pain in patients undergoing total knee arthroplasty surgery.",[209,287,28],"Knee Pain Chronic","2026-06-19",{"date":290,"type":35},"2026-06-23",{"date":292,"type":35},"2024-04-16",{"date":294,"type":22},"2027-12-31",{"name":296,"class":42},"University Health Network, Toronto",3,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":321,"locationsCount":43},"100600211","phase-2-jaw-muscle-pain-post-wisdom-molar-surgery-100600211","NCT07094542","Jaw Muscle Pain Post Wisdom Molar Surgery","Temporo-masseteric Nerve Block in Post-wisdom Tooth Extraction Pain- a Randomized Study","Inclusion Criteria:\n\nAll patients recommended extraction\u002Fs of at least 1 lower wisdom (third) molar that is partially\u002Ffully 'impacted' under intravenous sedation, are eligible to participate in this study so long as they\n\n* are 18 years or older,\n* are healthy,\n* have no cognitive\u002Fintellectual disability,\n* have no past\u002Frecent pain or reduced range of motion in their jaw joint\u002F muscle complex, no trauma or surgery in their jaw region.\n* have an electronic device such as a smart phone or a tablet\u002F computer with internet connection.\n* are willing to participate in the study and not be excluded by the following criteria below.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Compromised ability to guard their self-interest, for e.g., prisoners, children, pregnant women, patients with intellectual\u002Fcognitive disability are not enrolled in the study.\n* Those patients who present with infection\u002Finflammation involving the third molars slated for extractions, on the day of their procedure, may not take part in the study.\n* Those who have had opioid pain medication\u002Fs in the past 3 months to address short term or long-standing pain, or those who are on long term prescription of anti-inflammatory pain medication, are unable to participate.\n* Those with long standing painful limitation of movement of the jaw joint or muscles.\n* Those patients who are allergic to\u002Funable to tolerate either the dental local anesthetic or its components, opioids, acetaminophen or ibuprofen also may not take part in the study",{"count":306,"type":22},80,[284],"The proposed design is a triple-blind, placebo-controlled randomized prospective phase II trial to assess the feasibility of employing the Temporo-masseteric Nerve Block (TMNB) injection to decrease jaw muscle pain, overall pain, improve mouth opening and minimize pain medication consumption. 80 participants undergoing lower third molar removal under sedation will be enrolled. Those who develop significant jaw muscle pain on the following day will be randomized to receive either the TMNB injection or a placebo. Daily ecological momentary assessments (EMAs) will be collected reflecting elements of patient experience for all participants. On Day 8, participants return for an end-of-study evaluation and return their unused pain medications. Up to 40 participants who are randomized to receive TMNB\u002Fplacebo will be recruited to participate in a qualitative interview regarding their experience.",[28,310,311],"Impacted Third Molar Tooth","Muscle Pain",[313,314],"Temporo-masseteric Nerve Block","Jaw muscle pain","2026-06-17",{"date":317,"type":35},"2026-06-18",{"date":142,"type":22},{"date":320,"type":22},"2030-05",{"name":322,"class":42},"Rutgers, The State University of New Jersey",{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":228,"sex":17,"minAge":18,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":43},"100621819","outcomes-of-pulpotomy-and-root-canal-treatment-in-teeth-with-symptomatic-irreversible-pulpitis-100621819","NCT07375576","Outcomes of Pulpotomy and Root Canal Treatment in Teeth With Symptomatic Irreversible Pulpitis","Evaluation of the Outcomes of Total Pulpotomy, Radicular Pulpotomy, and Root Canal Treatment in Teeth With Extremely Deep Caries and Symptomatic Irreversible Pulpitis","Inclusion Criteria:\n\n* Healthy patients of both sexes, aged between 15 and 45 years, with no systemic diseases, will be screened for inclusion in the study. Strict eligibility criteria will be applied.\n\nThe patients included in the study must have restorable, extremely deep carious lesions in the mandibular first and second molars, and first and second premolars; healthy periodontal status (periodontal pocket ≤ 3 mm); and a clinical diagnosis of symptomatic irreversible pulpitis (history of spontaneous pain, pain persisting after removal of the stimulus, exaggerated and prolonged response to cold testing, and a positive response to the electric pulp test).\n\nExclusion Criteria:\n\n* Teeth with cracks or cusp fractures, subgingival caries, or periapical radiolucency will not be included in the study.\n\nInformed consent will be obtained from all included patients.","45 Years",{"count":332,"type":22},99,[25],"The aim of this study is to evaluate the clinical effectiveness of total pulpotomy (TP), radicular pulpotomy (RP), and root canal treatment (RCT) in mandibular premolar and\u002For molar teeth diagnosed with symptomatic irreversible pulpitis, with respect to postoperative pain control and treatment success.Materials and Methods:A total of 99 mandibular premolar and molar teeth will be included in this study. The teeth will be randomly allocated into three groups (n = 33 per group): total pulpotomy, radicular pulpotomy, and root canal treatment.Root canal treatment will be performed using standardized endodontic protocols.Total pulpotomy will be carried out to the level of the canal orifices, followed by hemostasis achieved with 2.5% sodium hypochlorite (NaOCl). A 3-mm-thick layer of mineral trioxide aggregate (MTA) will be placed as the pulpotomy material.Radicular pulpotomy will be performed by removing the pulp tissue a few millimeters apical to the canal orifices. Hemostasis will be achieved using 2.5% NaOCl, and a 3-mm-thick layer of MTA will be placed as the pulpotomy agent.All treated teeth will be restored with glass ionomer cement, followed by a composite resin restoration.Postoperative pain intensity will be assessed using a visual analog scale (VAS) at the following time points: preoperatively, and at 12 hours, 24 hours, 48 hours, and 7 days postoperatively. Clinical and radiographic evaluations will be performed at 3, 6, and 12 months to assess treatment success and periapical health.",[110,336,337],"Pulpitis - Irreversible","Success Rate",[339,340,341,342,343,344,345,346,347],"irreversibl pulpitis","total pulpotomy","radicular pulpotomy","vital pulp therapy (VPT)","root canal treatment (RCT)","pain assessment","vas scale","clinical follow - up","radiographic evaluation","2026-06-04",{"date":350,"type":35},"2026-06-05",{"date":217,"type":35},{"date":353,"type":22},"2027-08-01",{"name":355,"class":42},"Mustafa Kemal University",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":228,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":43},"100549454","phase-4-opioid-use-after-laparoscopic-salpingectomy-100549454","NCT06434233","Opioid Use After Laparoscopic Salpingectomy","A Randomized Control Trial for Opioid Use After Laparoscopic Salpingectomy","Inclusion Criteria:\n\n* Individuals with a fallopian tube (unilateral and\u002For bilateral)\n* Age 18 years old and above\n* Undergoing minimally invasive (laparoscopic or robotic) unilateral or bilateral salpingectomy or other tubal sterilization procedure as the primary procedure\n* Benign indications for salpingectomy\u002Ftubal sterilization\n* Agreeing to participate\n\nExclusion Criteria:\n\n* Chronic pain syndromes patients including fibromyalgia\n* Patients currently on long-term (i.e. for more than three months) opioid use\n* Conversion to laparotomy\n* Allergy or other contraindication to the prescribed medications such as acetaminophen or oxycodone\n* Salpingectomy that occurs in conjunction with a major Gyn surgery (i.e. hysterectomy, etc)\n* Salpingectomy performed for treatment of ectopic pregnancy\n* Patients with a history of gastritis and\u002For GI bleeding",{"count":364,"type":22},38,[105],"The purpose of this study is to evaluate patient-reported post-operative pain scores following minimally invasive tubal sterilization procedures to determine if a multimodal, non-opioid pain control regimen is non-inferior to a pain control regimen including opioids.\n\nThe study team hypothesizes that with extensive counseling on pain management, multimodal medication use, and expectation with non-opioid methods can effectively eliminate the need for opioid prescriptions after laparoscopic salpingectomy.",[57,110,368],"Sterility, Female","2026-06-01",{"date":371,"type":35},"2026-06-03",{"date":373,"type":35},"2024-04-25",{"date":37,"type":22},{"name":376,"class":42},"Johns Hopkins University",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":398,"locationsCount":43},"100528273","phase-1-intra-nasal-ketorolac-for-acute-ureteral-stent-associated-pain-following-ureteroscopy-for-stone-disease-100528273","NCT06158620","Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease","Intra-nasal Ketorolac Versus Oral Diclofenac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease","Inclusion Criteria:\n\n* ≥18 years old\n* English-speaking\n* Candidate for unilateral ureteroscopy for treatment of urolithiasis\n* Surgical plan includes placement of a ureteral stent\n\nExclusion Criteria:\n\n* Pregnant\u002Fnursing, prisoners, cognitively impaired\n* Solitary kidney\n* Stone in transplant kidney\n* Anatomic abnormalities (i.e., ureteral stricture, infundibular stenosis, uretero-pelvic junction obstruction, horseshoe kidney, duplicated system)\n* History of ureteral reconstruction\n* History of nephrocalcinosis, medullary sponge kidney, cystinuria\n* Immobility or relative immobility\n* Planned staged ureteroscopy\n* History of ureteral stent complication or poor tolerance or a ureteral stent\n* Urinary tract infection or sepsis\n* Current anticoagulation use (81 mg Aspirin permissible)\n* NSAID contraindication (acute renal failure or chronic kidney disease, bleeding disorders, allergic reaction to NSAIDs, ulcer disease, auto-immune disease)",{"count":306,"type":22},[386,284],"PHASE1","Objective: To improve quality-of-life and health care delivery to patients receiving ureteral stents.\n\nSpecific Aims: Evaluate the feasibility, practicality, and qualitative outcomes of utilizing intra-nasal ketorolac in patients with indwelling ureteral stents (Phase I), followed by a randomized trial comparing two non-steroidal anti-inflammatory drugs, intra-nasal Ketorolac versus oral Diclofenac.\n\nHypotheses: Due to its favorable pharmacokinetics in relieving acute pain, investigators expect improved pain scores and a lower rate of unplanned clinical encounters in patients receiving intra-nasal ketorolac compared to those taking oral diclofenac following ureteroscopic surgery for urolithiasis.\n\nStudy Rationale: Following ureteroscopic management of urolithiasis, patient with indwelling ureter stents have higher levels of discomfort compared to those without a ureter stent. Prior studies showed that intramuscular Ketorolac at time of ureter stent removal decreased the incidence of unplanned clinical encounters. Furthermore, onset of analgesic effect by intra-nasal ketorolac is faster than its oral form, and similar its intramuscular and intravenous counterparts.",[28,389,390,391],"Urolithiasis","Ureter Calculi","Stent Complication","2026-05-22",{"date":394,"type":35},"2026-05-27",{"date":396,"type":35},"2025-03-01",{"date":120,"type":22},{"name":399,"class":42},"University of Texas Southwestern Medical Center",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":407,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":43},"100639430","comparison-of-qlb-and-tfp-block-for-postoperative-analgesia-in-laparoscopic-inguinal-hernia-100639430","NCT07604259","Comparison of QLB and TFP Block for Postoperative Analgesia in Laparoscopic Inguinal Hernia","Comparison of the Effects of Ultrasound-Guided Lateral Quadratus Lumborum Block and Transversalis Fascia Plane Block on Postoperative Analgesia in Patients Undergoing Laparoscopic Inguinal Hernia Repair: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Scheduled for elective laparoscopic inguinal hernia repair.\n* American Society of Anesthesiologists (ASA) physical status I, II, or III.\n* Age between 18 and 65 years.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* History of allergy to local anesthetics.\n* Presence of coagulopathy.\n* Signs of infection at the intended block application site.\n* Body Mass Index (BMI) ≥ 35 kg\u002Fm².\n* History of chronic opioid use.\n* Presence of neurological disease.\n* Refusal to participate in the study.",{"count":408,"type":22},90,[25],"This randomized controlled trial aims to compare the effects of ultrasound-guided lateral Quadratus Lumborum Block (QLB) and Transversalis Fascia Plane (TFP) block on postoperative analgesia in patients undergoing laparoscopic inguinal hernia repair. Ninety patients will be randomly assigned to one of three groups: Group QLB, Group TFP, or Group Control. The primary objective is to compare postoperative pain scores (NRS) at various time points within the first 24 hours. Secondary objectives include evaluating the need for rescue analgesia, total tramadol consumption, and the incidence of opioid-related side effects.",[412,28],"İnguinal Hernia",[414],"Laparoscopic inguinal hernia, Quadratus Lumborum Block, Transversalis Fascia Plane Block, Postoperative analgesia, Regional anesthesia.","2026-05-18",{"date":392,"type":35},{"date":418,"type":22},"2026-06-10",{"date":420,"type":22},"2027-05-10",{"name":422,"class":42},"Medipol University",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":23,"phases":433,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":443,"leadSponsor":445,"locationsCount":43},"100634433","phase-3-suzetrigine-enhanced-multimodal-opioid-sparing-therapy-in-cardiac-and-bariatric-surgery-100634433","NCT07539623","Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery","SMOOTH-SURG","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Adults 18-85 years old\n* Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)\n* All genders\n\nExclusion Criteria:\n\nAny individual who meets any of the following criteria will be excluded from participation in this study:\n\n* ASA Class V\n* Urgent or emergent surgery\n* Contraindications to administration of Suzetrigine (e.g. concomitant use of strong CYP3A inhibitors)\n* History of substance use disorder or chronic opioid use\n* Reoperation\n* Patient refusal or inability to consent\n* Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and\n* Clarithromycin)\n* Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)","85 Years",{"count":432,"type":22},235,[434],"PHASE3","This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.",[437,438,110],"Bariatric Surgery","Cardiac Surgery With Sternotomy","2026-05-11",{"date":441,"type":35},"2026-05-14",{"date":64,"type":35},{"date":444,"type":22},"2026-12-22",{"name":446,"class":42},"Icahn School of Medicine at Mount Sinai",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":455,"minAge":130,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":43},"100636911","modulation-of-periapical-inflammation-following-nano-sized-intracanal-medication-a-randomized-controlled-clinical-trial-100636911","NCT07571837","Modulation of Periapical Inflammation Following Nano-sized Intracanal Medication. A Randomized Controlled Clinical Trial","Modulation of Periapical Inflammation Following Nano-Calcium Hydroxide and Nano-Chitosan Intracanal Medications in Endodontic Retreatment Cases: A Randomized Controlled Clinical Trial","Nano-Chitosan","Inclusion Criteria:\n\nPatients have single rooted teeth with root canal form type I. Have previous endodontic therapy with failure. Have periapical radiolucency (PAI score of 3 or 4). Asymptomatic patients who had no pain or swelling, had a negative response to palpation and percussion.\n\nExclusion Criteria:\n\nPatients who had received antibiotic therapy within the past 3 months. Pregnancy and lactation. Systemic disease. Physical or mental disability. Non-restorable teeth. Any signs of resorption, immature roots, fracture, sinus tract and dental anomaly","MALE","40 Years",{"count":458,"type":22},63,[25],"The main cause of endodontic disorders is microbial infection. From the infected pulp tissue, microorganisms can penetrate into the deeper layers of root dentine and propagate a periapical tissue through the apical foramen and lateral canals causing apical periodontitis. Apical periodontitis is an inflammatory condition affecting the periapical area of teeth with a global prevalence of 52% among individuals and 5% at tooth level. At the periapical region, microbes and their products encounter the host immune defense. Innate immune cells combat bacteria through phagocytosis and release anti-microbial substances, while adaptive immune cells initiate both cell-mediated and humoral immune responses. This immune activation also stimulates osteoclasts, leading to bone resorption and creating space for the inflammatory cells' infiltration . During periapical inflammation, immune cells migrate to the periapical area, where they release pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), along with anti-inflammatory cytokines like interleukin-10 (IL-10). These cytokines play crucial roles in modulating inflammation and tissue repair.\n\nMicroRNAs (miRNAs) are evolutionarily conserved small (18-22 nucleotides) single-stranded, noncoding RNAs. It has been well acknowledged that miRNAs influence gene expression at the posttranscriptional level by targeting mRNA 3'-untranslated regions (3'-UTRs). Accumulating evidence has suggested that miRNA expression is related to the clinical and biological features of diverse diseases, and they can be potential biomarkers for diagnosis, treatment, and prognosis. miRNAs have revealed their critical roles in regulating various cellular functions, including proliferation, apoptosis, differentiation, metabolism, and tumorigenesis, by targeting specific mRNAs.\n\nMiR-146a regulates innate immunity, inflammatory responses, and the antiviral pathway. Changes in miR-146a expression have been noted in many human diseases, including autoimmune disorders and cancers. In addition, miR-146a is an important biomarker of disease diagnosis, prevention, and treatment. It is a negative regulator of inflammatory responses by suppressing target gene expression. However, limited data is available regarding the functional role of miR-146a in modulating the inflammatory response of periapical tissues following root canal disinfection in endodontic retreatment cases.\n\nEliminating microorganisms is the primary objective of root canal therapy in order to create an environment as free of bacteria as possible. However, not all root canal treatments are completely successful, and in some cases, the infection persists leading to development of secondary apical periodontitis in previously treated teeth.\n\nDisinfecting the root canal during retreatment is significantly more challenging due to the presence of persistent microorganisms that have settled in the root canal system. These microbes are often resistant to standard irrigations and antimicrobial agents leading to the formation of periradicular lesions. Such bacteria can survive for extended periods around the previously filled root canals. Sodium hypochlorite (NaOCl) is the most widely used irrigant in root canal therapy due to its strong antibacterial effect and its ability to dissolve organic substances. Effective canal cleaning is difficult to achieve without the use of NaOCl at a sufficiently high concentration. However, NaOCl has several drawbacks, including its cytotoxicity which can lead to tissue damage and patient symptoms. Additionally, its strong oxidizing nature negatively affects the mechanical properties of dentin such as microhardness and elastic modulus. NaOCl should be used with caution in endodontic procedures to prevent hypochlorite accidents.\n\nCalcium hydroxide (Ca (OH)2) is the most widely utilized intracanal medication. It has the potential to dissolve tissue, acts as a physical barrier and generates hydroxyl ions, creating an extremely alkaline environment. It has been shown to be quite effective in the treatment of teeth with persistent periapical lesions. To provide optimal endodontic treatment, the root canal system should be thoroughly cleaned of soft-tissue debris, smear layer, and bacteria. Nanoparticles (NPs) have unique characteristics such as smaller sizes, increased surface area to volume ratio, and higher chemical reactivity and charge density leading to greater interaction with the environment and negatively charged bacterial cells, compared to their bulk counterparts. These advantages can be used to design highly anti-microbial agents with maximal therapeutic efficacy and minimal side effects.",[110,462],"Periapical Inflammation",[462,464,453,465],"Nano-Calcium Hydroxide","Endodontic Retreatment","2026-05-03",{"date":468,"type":35},"2026-05-06",{"date":470,"type":35},"2026-02-01",{"date":472,"type":22},"2027-01-30",{"name":474,"class":42},"Al-Azhar University",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":483,"maxAge":4,"enrollmentInfo":484,"targetDuration":486,"studyType":259,"phases":4,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":43},"100215602","pain-out-improvement-in-postoperative-pain-outcome-100215602","NCT02083835","PAIN OUT: Improvement in Postoperative PAIN OUTcome","Improvement in Postoperative Pain Outcome","PAIN-OUT","Inclusion Criteria:\n\n* \\>= 18 years or \\>= 4 years for sub-project QUIPSI\u002FPAIN OUTinfant\n* patient is post-op day 1\n* patient is at least 6 hours on the ward\n* patient has given consent\n\nExclusion Criteria:\n\n* patient cannot communicate\n* patient is cognitively impaired\n* patient is asleep\n* patient is too ill\n* patient does not want to fill in the questionnaire","4 Years",{"count":485,"type":22},200000,"12 Months","PAIN OUT is a multi-national, non-interventional registry and benchmark project, assessing and analysing clinical and patient-reported outcome data of postoperative pain.",[110],[490,491,492],"post-operative pain","paitent reported outcomes","quality improvement","2026-04-30",{"date":468,"type":35},{"date":496,"type":35},"2009-01",{"date":498,"type":22},"2030-12-31",{"name":500,"class":42},"University of Jena",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":43},"100635734","comparison-of-serratus-intercostal-plane-blcok-with-erector-spinae-plane-block-for-open-nephrectomy-100635734","NCT07556536","Comparison of Serratus Intercostal Plane Blcok With Erector Spinae Plane Block for Open Nephrectomy","Analgesic Efficacy of Ultrasound-Guided Serratus Intercostal Plane Block Versus Erector Spinae Plane Block for Postoperative Pain Control After Open Nephrectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective open nephrectomy under general anesthesia via flank incision .\n2. Adult patients aged 18-65 years.\n3. Patients with an American Society of Anesthesiologists (ASA) physical status I to III.\n\nExclusion Criteria:\n\n1. Patient refusal.\n2. Allergy to local anesthetics and patient with infection at the injection site of block.\n3. Coagulation disorders or ongoing anticoagulant therapy.\n4. Patients receiving opioids for chronic analgesic therapy (cancer, addiction).\n5. Cognitive impairment preventing pain scoring.\n6. Neurological or psychiatric disorders affecting pain assessment.",{"count":509,"type":22},132,[25],"Effective postoperative pain management following open nephrectomy remains a significant clinical challenge.\n\nInadequate pain control after this procedure may lead to impaired respiratory function, delayed mobilization, prolonged hospital stay, increased opioid consumption, and a higher incidence of postoperative complications. Therefore, optimizing postoperative analgesia while minimizing opioid-related adverse effects is a key objective in perioperative care for patients undergoing open nephrectomy Traditionally, postoperative pain following open nephrectomy has been managed using systemic opioids, epidural analgesia, or paravertebral blocks.\n\nUltrasound-guided fascial plane blocks have emerged as valuable alternatives in modern regional anesthesia due to their simplicity, safety profile, and effectiveness. Among these techniques, the erector spinae plane (ESP) block has gained widespread popularity.\n\nThis block has been shown to provide effective analgesia for thoracic, abdominal, and urologic surgeries, including nephrectomy The ultrasound-guided serratus intercostal plane block (SIPB) is a more recently described regional anesthetic technique targeting the lateral cutaneous branches of the intercostal nerves by injecting local anesthetic between the serratus anterior muscle and the intercostal muscles or ribs By blocking these nerves, SIPB provides analgesia to the lateral thoracic wall and upper abdominal regions, which are particularly relevant to flank incisions used in open nephrectomy.\n\nPatients will be randomly allocated into two equal groups. Patients in group (S) will receive serratus intercostal plane block and those in group (E) will receive Erector spinae plane block . Both of these blocks will be performed after induction of general anaesthesia by an experienced anaesthesiologist The aim of this study is to to compare the analgesic efficacy of ultrasound-guided serratus intercostal plane block and erector spinae plane block in patients undergoing open nephrectomy.",[28,513],"Open Nephrectomy",[515,516,517],"serratus intercostal plane block","Erector spinae plane block","open nephrectomy","2026-04-22",{"date":520,"type":35},"2026-04-29",{"date":522,"type":35},"2026-04-10",{"date":524,"type":22},"2027-06-01",{"name":526,"class":42},"Fayoum University Hospital",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":259,"phases":4,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":548,"locationsCount":43},"100634993","comparison-of-analgesic-efficacy-of-suprainguinal-fascia-iliaca-and-quadro-iliac-blocks-in-hip-fracture-surgery-100634993","NCT07546903","Comparison of Analgesic Efficacy of Suprainguinal Fascia Iliaca and Quadro-iliac Blocks in Hip Fracture Surgery","Comparison of the Postoperative Analgesic Efficacy of Ultrasound-Guided Suprainguinal Fascia Iliaca Block and Quadro-Iliac Plane Block in Patients Undergoing Hip Fracture Surgery","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* ASA physical status I-III\n* Hemodynamically stable patients\n* Scheduled for surgical treatment of hip fracture\n* Body mass index (BMI) ≤ 35 kg\u002Fm²\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* ASA physical status IV-V\n* Hemodynamically unstable patients\n* Surgery not completed as planned\n* Infection at the block site\n* History of allergy to local anesthetics or tramadol\n* Presence of neuromuscular or peripheral nerve diseases\n* Chronic pain conditions\n* Coagulopathy or ongoing anticoagulant therapy\n* High-dose opioid use within the last 3 days\n* Severe hepatic or renal insufficiency\n* Diabetes mellitus\n* Pregnancy or breastfeeding\n* NRS score \\>7 for four consecutive hours despite multimodal analgesia\n* Inability to understand or use assessment tools (e.g., NRS, QoR-15)\n* Inability to communicate in Turkish\n* Inability to use PCA device due to technical reasons",{"count":535,"type":22},70,"Hip fractures are common in the elderly and are associated with significant morbidity and mortality. Effective early analgesia is crucial for facilitating mobilization, reducing pulmonary complications, and improving overall outcomes. Although opioids are traditionally used for postoperative pain management, their adverse effects have led to increased interest in multimodal analgesia, particularly peripheral nerve blocks.\n\nThe suprainguinal fascia iliaca block (SIFI) is a modified technique that allows wider spread of local anesthetic, providing more effective blockade of the femoral, obturator, and lateral femoral cutaneous nerves. The quadro-iliac plane block (QIPB), a recently described interfascial block, is performed at the level of the anterior superior iliac spine and may also affect branches of the lumbar and sacral plexus.\n\nWhile both techniques have been shown to provide effective analgesia and reduce opioid consumption, there is no study directly comparing them. Therefore, this study aims to compare the postoperative analgesic efficacy of SIFI and QIPB in patients undergoing hip fracture surgery.",[28],[539,540,541],"Hip Fracture","Suprainguinal Fascia Iliaca Block","Quadro-Iliac Plane Block","2026-04-20",{"date":544,"type":35},"2026-04-23",{"date":90,"type":35},{"date":547,"type":22},"2026-06-15",{"name":549,"class":42},"Hitit University",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":558,"maxAge":559,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":43},"100634515","the-analgesic-efficacy-of-m-tapa-for-laparoscopic-abdominal-surgery-in-children-100634515","NCT07540689","The Analgesic Efficacy of M-TAPA for Laparoscopic Abdominal Surgery in Children","The Analgesic Efficacy of Modified Thoracoabdominal Nerve Block Through Perichondrial Approach for Laparoscopic Abdominal Surgery in Children: Randomized Controlled Trial","M-TAPA","Inclusion Criteria:\n\n* Age (1-7) years.\n* Both genders.\n* American Society of Anaesthesiologists (ASA) - physical status I-II.\n* Children undergoing elective laparoscopic abdominal surgery.\n\nExclusion Criteria:\n\n* Parental refusal.\n* Bleeding disorders with INR \\> 1.5 and\u002For platelets \\\u003C 50 000.\n* History of allergic reactions to local anesthetics.\n* Rash or signs of infection at the injection site.","1 Year","7 Years",{"count":21,"type":22},[25],"This investigation aims to assess the efficacy of M-TAPA in children undergoing laparoscopic abdominal surgery.\n\nSixty pediatric patients undergoing laparoscopic abdominal surgery under general anesthesia will be enrolled in this single-center study. Preoperatively, participants will be randomly assigned to receive either port-site local anesthetic infiltration or M-TAPA.",[28],{"date":544,"type":35},{"date":566,"type":22},"2026-05",{"date":568,"type":22},"2027-04",{"name":41,"class":42},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":430,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":43},"100635107","phase-3-suzetrigine-for-treatment-and-reduction-of-intense-discomfort-after-knee-replacement-pain-100635107","NCT07548385","Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN","STRIDE-PAIN","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Adults 18-85 years old\n* Scheduled to undergo total knee replacement surgery\n* All genders\n\nExclusion Criteria:\n\nAny individual who meets any of the following criteria will be excluded from participation in this study:\n\n* American Society of Anesthesiology Physical Classification (ASA) Class V\n* Urgent or emergent surgery\n* Contraindications to administration of Suzetrigine:\n\n  * Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and Clarithromycin)\n  * Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)\n  * Patients with moderate to severe hepatic impairment\n* History of substance use disorder or chronic opioid use or alcohol abuse\n* Reoperation\n* Patient refusal or inability to consent\n* Pregnancy",{"count":432,"type":22},[434],"This is a prospective, randomized study. The purpose of this study is to evaluate if the addition of Suzetrigine, a new pain medication, to well established peri-operative pain regimen used for total knee replacement surgery will effect pain control.\n\n1. Does Suzetrigine given pre-operatively decrease the total opioid consumed after total knee replacement surgery?\n2. Dose Suzetrigine given pre-operatively decrease the visual analog pain scale pain scores after total knee replacement surgery? Study participants will be randomly assigned to receive either Suzetrigine medication or placebo medication.",[581,110],"Total Knee Replacement Surgery","2026-04-16",{"date":544,"type":35},{"date":585,"type":22},"2026-04",{"date":587,"type":22},"2027-02-23",{"name":446,"class":42},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":228,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":43},"100512539","phase-2-presacral-nerve-block-versus-sham-block-on-post-operative-pain-for-total-laparoscopic-hysterectomy-100512539","NCT05953766","Presacral Nerve Block Versus Sham Block on Post-operative Pain for Total Laparoscopic Hysterectomy","A Randomized Controlled Trial (RCT) Comparing Presacral Nerve Block Versus Sham Block on Post-operative Pain in Women Undergoing Total Laparoscopic Hysterectomy.","Inclusion Criteria:\n\n* 18 years of age or older\n* Undergoing total laparoscopic hysterectomy\n\nExclusion Criteria:\n\n* Previous presacral neurectomy\n* Concurrent surgical procedure other than salpingectomy and\u002For oophorectomy\n* Gynecological cancer beyond stage 1 disease\n* BMI \\> 50\n* Chronic opioid consumption\n* Fibromyalgia\n* Language barrier\n* Inability to communicate and provide consent",{"count":21,"type":22},[284],"The study is a single-center parallel group randomized controlled trial comparing the administration of a presacral nerve block using 20mL of local ropivacaine 5.0mg\u002Fml versus 20mL of normal saline (sham block) on post-operative pain following total laparoscopic hysterectomy.",[110],[601,602,603,604],"Hysterectomy","Presacral nerve block","Laparoscopy","Anesthesia","2026-03-31",{"date":607,"type":35},"2026-04-06",{"date":609,"type":35},"2025-09-24",{"date":611,"type":22},"2026-07",{"name":613,"class":42},"Mount Sinai Hospital, Canada",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":623,"briefSummary":624,"conditions":625,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":43},"100592269","the-benefits-of-cryoablation-in-patients-undergoing-total-knee-arthroplasty-100592269","NCT06991231","The Benefits Of Cryoablation In Patients Undergoing Total Knee Arthroplasty","The Benefits Of Cryoablation In Patients Undergoing Total Knee Arthroplasty - A Randomized Prospective Clinical Trial","Inclusion Criteria:\n\n* Patients are candidates for elective primary total knee arthroplasty for a diagnosis of osteoarthritis or inflammatory arthritis.\n* Patients have been medically cleared and scheduled for surgery\n\nExclusion Criteria:\n\n* Patients with cold-related conditions (cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, and Raynaud's disease)\n* Surgery for fracture, infection, or malignancy",{"count":622,"type":22},215,[25],"The purpose of this study is to evaluate the efficacy of cryoablation use on patient-reported outcomes (PROMs) and opioid consumption following total knee arthroplasty. This is a randomized study that will involve a 1:1 randomization to total knee arthroplasty +\u002F- cryoablation.",[626,627],"Post-Operative Pain","Total Knee Arthroplasty","2026-03-30",{"date":630,"type":35},"2026-04-03",{"date":632,"type":35},"2025-06-13",{"date":634,"type":22},"2027-01-01",{"name":636,"class":42},"NYU Langone Health"]